Emerging role of GLP-1RAs in the management of diabetic kidney disease

Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 2016;316(6):602-10. https://doi.org/10.1001/jama.2016.10924

Kidney Research UK. Kidney disease: a UK public health emergency. The health economics of kidney disease to 2033; published 2023.kidneyresearchuk.org

Holliday MW Jr, Frost L, Navaneethan SD. Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression. Curr Opin Nephrol Hypertens 2024;33(3):331-6. https://doi.org/10.1097/MNH.0000000000976

Huart J, Jouret F. Non-steroidal mineralocorticoid receptor antagonists: a paradigm shift in the management of diabetic nephropathy. Kidney Blood Press Res 2025;50(1):267-75. https://doi.org/10.1159/000545286

Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9(10):653-62. https://doi.org/10.1016/S2213-8587(21)00203-5

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391(2):109-21. https://doi.org/10.1056/NEJMoa2403347

Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 2024;30(7):2058-66. https://doi.org/10.1038/s41591-024-03015-5

Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2025;13(1):15-28. https://doi.org/10.2337/dc25-0241

Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol 2022;10(11):774-85. https://doi.org/10.1016/S2213-8587(22)00243-1

Caruso I, Giorgino F. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future. Endocrine 2024;84(3):822-35. https://doi.org/10.1007/s12020-024-03757-9

Bjornstad P, Cherney D, Lawson J, et al. MO399. Remodel: a mechanistic trial evaluating the effects of semaglutide on the kidneys in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation 2022;37:gfac070.013. https://doi.org/10.1093/ndt/gfac070.013

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45(11):2753-86. https://doi.org/10.2337/dci22-0034

Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022;102(5S):S1-S127. https://doi.org/10.1016/j.kint.2022.06.008